| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | gossypol | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |